Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 77 articles:
HTML format
Text format



Single Articles


    March 2019
  1. PARIKH RR, Saraiya B
    Multidisciplinary Care in High-Risk Prostate Cancer Is the New Standard of Care.
    J Clin Oncol. 2019 Mar 22:JCO1900298. doi: 10.1200/JCO.19.00298.
    PubMed     Text format    


  2. ARMSTRONG AJ, Halabi S, Luo J, Nanus DM, et al
    Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
    J Clin Oncol. 2019 Mar 13:JCO1801731. doi: 10.1200/JCO.18.01731.
    PubMed     Text format     Abstract available


  3. ROSENTHAL SA, Hu C, Sartor O, Gomella LG, et al
    Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.
    J Clin Oncol. 2019 Mar 12:JCO1802158. doi: 10.1200/JCO.18.02158.
    PubMed     Text format     Abstract available


  4. JAYADEVAPPA R, Chhatre S, Gallo JJ, Wittink M, et al
    Patient-Centered Preference Assessment to Improve Satisfaction With Care Among Patients With Localized Prostate Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2019 Mar 12:JCO1801091. doi: 10.1200/JCO.18.01091.
    PubMed     Text format     Abstract available


    February 2019
  5. GULLEY JL, Borre M, Vogelzang NJ, Ng S, et al
    Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2019 Feb 28:JCO1802031. doi: 10.1200/JCO.18.02031.
    PubMed     Text format     Abstract available


  6. VAPIWALA N, Hofman MS, Murphy DG, Williams S, et al
    Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart.
    J Clin Oncol. 2019 Feb 22:JCO1801927. doi: 10.1200/JCO.18.01927.
    PubMed     Text format    


    January 2019
  7. CASTRO E, Romero-Laorden N, Del Pozo A, Lozano R, et al
    PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2019 Jan 9:JCO1800358. doi: 10.1200/JCO.18.00358.
    PubMed     Text format     Abstract available


    December 2018
  8. DAVID J, Kamrava M
    Prostate Cancer Radiotherapy: An Evolving Paradigm That Should Also Include High-Dose-Rate Monotherapy.
    J Clin Oncol. 2018 Dec 28:JCO1801482. doi: 10.1200/JCO.18.01482.
    PubMed     Text format    


  9. HALABI S, Dutta S, Tangen CM, Rosenthal M, et al
    Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
    J Clin Oncol. 2018 Dec 21:JCO1801279. doi: 10.1200/JCO.18.01279.
    PubMed     Text format     Abstract available


  10. PARIKH RB, Prasad V
    Metastasis-Free Survival in Prostate Cancer: Faster Drug Approvals, Better Drugs?
    J Clin Oncol. 2018 Dec 11:JCO1801092. doi: 10.1200/JCO.18.01092.
    PubMed     Text format    


  11. DIGNAM JJ, Hamstra DA, Lepor H, Grignon D, et al
    Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202.
    J Clin Oncol. 2018 Dec 7:JCO1800154. doi: 10.1200/JCO.18.00154.
    PubMed     Text format     Abstract available


    October 2018
  12. MORGAN SC, Hoffman K, Loblaw DA, Buyyounouski MK, et al
    Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.
    J Clin Oncol. 2018 Oct 11:JCO1801097. doi: 10.1200/JCO.18.01097.
    PubMed     Text format    


    September 2018
  13. GOMEZ-ITURRIAGA A, Crook J
    High-Risk Localized Prostate Cancer: How Important Is the Addition of Brachytherapy to External-Beam Radiotherapy?
    J Clin Oncol. 2018 Sep 13:JCO1800704. doi: 10.1200/JCO.18.00704.
    PubMed     Text format    


  14. VELHO PI, Eisenberger MA
    There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive.
    J Clin Oncol. 2018 Sep 6:JCO2018793166. doi: 10.1200/JCO.2018.79.3166.
    PubMed     Text format    


  15. BEKELMAN JE, Rumble RB, Chen RC, Pisansky TM, et al
    Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.
    J Clin Oncol. 2018 Sep 5:JCO1800606. doi: 10.1200/JCO.18.00606.
    PubMed     Text format     Abstract available


    August 2018
  16. CATTON CN, Lukka H, Martin J
    Prostate Cancer Radiotherapy: An Evolving Paradigm.
    J Clin Oncol. 2018 Aug 23:JCO2018793257. doi: 10.1200/JCO.2018.79.3257.
    PubMed     Text format     Abstract available


  17. HOFFMAN KE, Voong KR, Levy LB, Allen PK, et al
    Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer.
    J Clin Oncol. 2018 Aug 14:JCO2018779868. doi: 10.1200/JCO.2018.77.9868.
    PubMed     Text format     Abstract available


    July 2018
  18. ATTARD G, Borre M, Gurney H, Loriot Y, et al
    Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment.
    J Clin Oncol. 2018 Jul 20:JCO2018779827. doi: 10.1200/JCO.2018.77.9827.
    PubMed     Text format     Abstract available


  19. AGGARWAL R, Huang J, Alumkal JJ, Zhang L, et al
    Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
    J Clin Oncol. 2018 Jul 9:JCO2017776880. doi: 10.1200/JCO.2017.77.6880.
    PubMed     Text format     Abstract available


    June 2018
  20. REN C, Han C, Wang D, Chen H, et al
    Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen?
    J Clin Oncol. 2018 Jun 12:JCO2018781401. doi: 10.1200/JCO.2018.78.1401.
    PubMed     Text format    


  21. BIBAULT JE, Blanchard P
    Treating Metastatic Prostate Cancer With Local Therapies: Is It Still Wishful Thinking?
    J Clin Oncol. 2018 Jun 1:JCO2017775429. doi: 10.1200/JCO.2017.77.5429.
    PubMed     Text format    


  22. CATTRINI C, Zanardi E, Boccardo F
    Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate Cancer.
    J Clin Oncol. 2018 Jun 1:JCO2018780031. doi: 10.1200/JCO.2018.78.0031.
    PubMed     Text format    


    May 2018
  23. SPRATT DE, Carroll PR
    Optimal Radical Therapy for Localized Prostate Cancer: Recreation of the Self-Fulfilling Prophecy With Combination Brachytherapy?
    J Clin Oncol. 2018 May 21:JCO2018786236. doi: 10.1200/JCO.2018.78.6236.
    PubMed     Text format    


  24. BEKELMAN JE
    A Younger Man With Localized Prostate Cancer Asks, "Which Type of Radiation Is Right for Me?"
    J Clin Oncol. 2018 May 2:JCO2018777235. doi: 10.1200/JCO.2018.77.7235.
    PubMed     Text format     Abstract available


    April 2018
  25. JANSSON F, Drevin L, Frisell T, Stattin P, et al
    Concordance of Non-Low-Risk Disease Among Pairs of Brothers With Prostate Cancer.
    J Clin Oncol. 2018 Apr 13:JCO2017766907. doi: 10.1200/JCO.2017.76.6907.
    PubMed     Text format     Abstract available


  26. SARTOR O
    Curing More Prostate Cancer: Thinking Through the Options.
    J Clin Oncol. 2018 Apr 6:JCO2018784835. doi: 10.1200/JCO.2018.78.4835.
    PubMed     Text format    


  27. HUSSAIN M, Tangen CM, Thompson IM Jr, Swanson GP, et al
    Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.
    J Clin Oncol. 2018 Apr 6:JCO2017764126. doi: 10.1200/JCO.2017.76.4126.
    PubMed     Text format     Abstract available


  28. MORRIS MJ, Rumble RB, Basch E, Hotte SJ, et al
    Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    J Clin Oncol. 2018 Apr 2:JCO2018780619. doi: 10.1200/JCO.2018.78.0619.
    PubMed     Text format     Abstract available


    March 2018
  29. SZMULEWITZ RZ, Peer CJ, Ibraheem A, Martinez E, et al
    Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2018 Mar 28:JCO2017764381. doi: 10.1200/JCO.2017.76.4381.
    PubMed     Text format     Abstract available


  30. PAN HY, Jiang J, Hoffman KE, Tang C, et al
    Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.
    J Clin Oncol. 2018 Mar 21:JCO2017755371. doi: 10.1200/JCO.2017.75.5371.
    PubMed     Text format     Abstract available


  31. MORGANS AK, Chen YH, Sweeney CJ, Jarrard DF, et al
    Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
    J Clin Oncol. 2018 Mar 9:JCO2017753335. doi: 10.1200/JCO.2017.75.3335.
    PubMed     Text format     Abstract available


    February 2018
  32. ENNIS RD, Hu L, Ryemon SN, Lin J, et al
    Brachytherapy-Based Radiotherapy and Radical Prostatectomy Are Associated With Similar Survival in High-Risk Localized Prostate Cancer.
    J Clin Oncol. 2018 Feb 28:JCO2017759134. doi: 10.1200/JCO.2017.75.9134.
    PubMed     Text format     Abstract available


  33. CHEN RC
    Challenges of Interpreting Registry Data in Prostate Cancer: Interpreting Retrospective Results Along With or in Absence of Clinical Trial Data.
    J Clin Oncol. 2018 Feb 28:JCO2017775833. doi: 10.1200/JCO.2017.77.5833.
    PubMed     Text format    


  34. TSAO CK, Oh WK
    First-Line Treatment of Hormone-Sensitive Metastatic Prostate Cancer: Is There a Single Standard of Care?
    J Clin Oncol. 2018 Feb 12:JCO2017774315. doi: 10.1200/JCO.2017.77.4315.
    PubMed     Text format    


  35. FAIENA I, Holden S, Cooperberg MR, Holden S, et al
    Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?
    J Clin Oncol. 2018 Feb 5:JCO2017764050. doi: 10.1200/JCO.2017.76.4050.
    PubMed     Text format    


    January 2018
  36. KYRIAKOPOULOS CE, Chen YH, Carducci MA, Liu G, et al
    Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
    J Clin Oncol. 2018 Jan 31:JCO2017753657. doi: 10.1200/JCO.2017.75.3657.
    PubMed     Text format     Abstract available


  37. HORIGUCHI M, Uno H, Wei LJ
    Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer.
    J Clin Oncol. 2018 Jan 26:JCO2017759829. doi: 10.1200/JCO.2017.75.9829.
    PubMed     Text format    


  38. ABIDA W, Sawyers CL
    Targeting DNA Repair in Prostate Cancer.
    J Clin Oncol. 2018 Jan 25:JCO2017766592. doi: 10.1200/JCO.2017.76.6592.
    PubMed     Text format    


  39. MORGANS AK
    Optimization of Risk Stratification in Localized Prostate Cancer.
    J Clin Oncol. 2018 Jan 5:JCO2017762971. doi: 10.1200/JCO.2017.76.2971.
    PubMed     Text format     Abstract available


    December 2017
  40. ANTONARAKIS ES
    Circulating Tumor Cell Eradication as an Intermediate Efficacy End Point for Metastatic Castration-Resistant Prostate Cancer: Is There Enough Evidence?
    J Clin Oncol. 2017 Dec 22:JCO2017765487. doi: 10.1200/JCO.2017.76.5487.
    PubMed     Text format    


  41. HELLER G, McCormack R, Kheoh T, Molina A, et al
    Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.
    J Clin Oncol. 2017 Dec 22:JCO2017752998. doi: 10.1200/JCO.2017.75.2998.
    PubMed     Text format     Abstract available


  42. ZHU Y, Ye D
    Measurement of Metastasis in the Follow-Up of Localized Prostate Cancer.
    J Clin Oncol. 2017 Dec 21:JCO2017762005. doi: 10.1200/JCO.2017.76.2005.
    PubMed     Text format    


  43. HARSHMAN LC, Chen YH, Liu G, Carducci MA, et al
    Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone Sensitive Prostate Cancer Treated With Androgen Deprivation With Or Without Docetaxel.
    J Clin Oncol. 2017 Dec 20:JCO2017753921. doi: 10.1200/JCO.2017.75.3921.
    PubMed     Text format     Abstract available


  44. HUSSAIN M, Daignault-Newton S, Twardowski PW, Albany C, et al
    Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
    J Clin Oncol. 2017 Dec 20:JCO2017757310. doi: 10.1200/JCO.2017.75.7310.
    PubMed     Text format     Abstract available


  45. PHILLIPS RM, Hayman J, Tran PT
    STOMPing Out Hormone-Sensitive Metastases With Local Therapies in Prostate Cancer.
    J Clin Oncol. 2017 Dec 14:JCO2017765495. doi: 10.1200/JCO.2017.76.5495.
    PubMed     Text format    


  46. OST P, Reynders D, Decaestecker K, Fonteyne V, et al
    Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
    J Clin Oncol. 2017 Dec 14:JCO2017754853. doi: 10.1200/JCO.2017.75.4853.
    PubMed     Text format     Abstract available


  47. GIRI VN, Knudsen KE, Kelly WK, Abida W, et al
    Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
    J Clin Oncol. 2017 Dec 13:JCO2017741173. doi: 10.1200/JCO.2017.74.1173.
    PubMed     Text format     Abstract available


    November 2017
  48. SPRATT DE, Zhang J, Santiago-Jimenez M, Dess RT, et al
    Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.
    J Clin Oncol. 2017 Nov 29:JCO2017742940. doi: 10.1200/JCO.2017.74.2940.
    PubMed     Text format     Abstract available


    October 2017
  49. CHEN DY, See LC, Liu JR, Chuang CK, et al
    Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study.
    J Clin Oncol. 2017 Oct 2:JCO2016714204. doi: 10.1200/JCO.2016.71.4204.
    PubMed     Text format     Abstract available


    September 2017
  50. RAJAN P, Sooriakumaran P, Nyberg T, Akre O, et al
    Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study.
    J Clin Oncol. 2017 Sep 20:JCO2016707794. doi: 10.1200/JCO.2016.70.7794.
    PubMed     Text format     Abstract available


    August 2017
  51. BAIK SH, Kury FSP, McDonald CJ
    Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.
    J Clin Oncol. 2017 Aug 25:JCO2017726109. doi: 10.1200/JCO.2017.72.6109.
    PubMed     Text format     Abstract available


  52. MUCCI LA, Kantoff PW
    Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?
    J Clin Oncol. 2017 Aug 17:JCO2017747915. doi: 10.1200/JCO.2017.74.7915.
    PubMed     Text format    


  53. EISENBERGER M, Hardy-Bessard AC, Kim CS, Geczi L, et al
    Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
    J Clin Oncol. 2017 Aug 15:JCO2016721076. doi: 10.1200/JCO.2016.72.1076.
    PubMed     Text format     Abstract available


  54. ZHANG T, Armstrong AJ
    The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2017 Aug 15:JCO2017747931. doi: 10.1200/JCO.2017.74.7931.
    PubMed     Text format    


  55. LARSEN SB, Dehlendorff C, Skriver C, Dalton SO, et al
    Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer.
    J Clin Oncol. 2017 Aug 14:JCO2016718981. doi: 10.1200/JCO.2016.71.8981.
    PubMed     Text format     Abstract available


  56. XIE W, Regan MM, Buyse M, Halabi S, et al
    Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
    J Clin Oncol. 2017 Aug 10:JCO2017739987. doi: 10.1200/JCO.2017.73.9987.
    PubMed     Text format     Abstract available


    July 2017
  57. OUDARD S, Fizazi K, Sengelov L, Daugaard G, et al
    Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
    J Clin Oncol. 2017 Jul 28:JCO2016721068. doi: 10.1200/JCO.2016.72.1068.
    PubMed     Text format     Abstract available


    June 2017
  58. HARMON SA, Perk T, Lin C, Eickhoff J, et al
    Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone.
    J Clin Oncol. 2017 Jun 27:JCO2017722348. doi: 10.1200/JCO.2017.72.2348.
    PubMed     Text format     Abstract available


  59. ANTONARAKIS ES, Tagawa ST, Galletti G, Worroll D, et al
    Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naive, Metastatic, Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2017 Jun 20:JCO2017724138. doi: 10.1200/JCO.2017.72.4138.
    PubMed     Text format     Abstract available


  60. BURRIS HA, Infante JR, Ansell SM, Nemunaitis JJ, et al
    Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
    J Clin Oncol. 2017;35:2028-2036.
    PubMed     Text format     Abstract available


  61. SPRATT DE, Yousefi K, Deheshi S, Ross AE, et al
    Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.
    J Clin Oncol. 2017;35:1991-1998.
    PubMed     Text format     Abstract available


    May 2017
  62. HOFFMAN RM, Lo M, Clark JA, Albertsen PC, et al
    Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study.
    J Clin Oncol. 2017 May 11:JCO2016706317. doi: 10.1200/JCO.2016.70.6317.
    PubMed     Text format     Abstract available


  63. PARIKH RR, Kim IY
    Can Genomic Data Guide the Postoperative Management of Prostate Cancer?
    J Clin Oncol. 2017 May 4:JCO2017724849. doi: 10.1200/JCO.2017.72.4849.
    PubMed     Text format    


  64. VAN DE WAL M, Thewes B, Gielissen M, Speckens A, et al
    Efficacy of Blended Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and Colorectal Cancer Survivors: The SWORD Study, a Randomized Controlled Trial.
    J Clin Oncol. 2017 May 4:JCO2016705301. doi: 10.1200/JCO.2016.70.5301.
    PubMed     Text format     Abstract available


  65. LOEB S, Folkvaljon Y, Damber JE, Alukal J, et al
    Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.
    J Clin Oncol. 2017;35:1430-1436.
    PubMed     Text format     Abstract available


    April 2017
  66. LECARPENTIER J, Silvestri V, Kuchenbaecker KB, Barrowdale D, et al
    Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
    J Clin Oncol. 2017 Apr 27:JCO2016694935. doi: 10.1200/JCO.2016.69.4935.
    PubMed     Text format     Abstract available


  67. VIRGO KS, Basch E, Loblaw DA, Oliver T, et al
    Second-Line Hormonal Therapy for Men With Chemotherapy-Naive, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
    J Clin Oncol. 2017 Apr 25:JCO2017728030. doi: 10.1200/JCO.2017.72.8030.
    PubMed     Text format     Abstract available


  68. PERNAR CH, Downer MK, Wilson KM, Stampfer MJ, et al
    Vasectomy and Risk of Prostate Cancer: How to Weigh Current Evidence.
    J Clin Oncol. 2017;35:1272-1273.
    PubMed     Text format    


  69. BUBLEY GJ, Balk SP
    Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide.
    J Clin Oncol. 2017 Apr 17:JCO2017728808. doi: 10.1200/JCO.2017.72.8808.
    PubMed     Text format    


  70. ANTONARAKIS ES, Lu C, Luber B, Wang H, et al
    Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
    J Clin Oncol. 2017 Apr 6:JCO2016701961. doi: 10.1200/JCO.2016.70.1961.
    PubMed     Text format     Abstract available


    March 2017
  71. YU JB
    Hypofractionated Radiotherapy for Prostate Cancer: Further Evidence to Tip the Scales.
    J Clin Oncol. 2017 Mar 29:JCO2017727016. doi: 10.1200/JCO.2017.72.7016.
    PubMed     Text format    


  72. ARCANGELI G, Saracino B, Arcangeli S, Gomellini S, et al
    Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial.
    J Clin Oncol. 2017 Mar 29:JCO2016704189. doi: 10.1200/JCO.2016.70.4189.
    PubMed     Text format     Abstract available


  73. DALELA D, Santiago-Jimenez M, Yousefi K, Karnes RJ, et al
    Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model.
    J Clin Oncol. 2017 Mar 28:JCO2016699918. doi: 10.1200/JCO.2016.69.9918.
    PubMed     Text format     Abstract available


  74. GARZOTTO M
    Is Low-Risk Prostate Cancer More Indolent in Younger Patients?
    J Clin Oncol. 2017 Mar 27:JCO2017723684. doi: 10.1200/JCO.2017.72.3684.
    PubMed     Text format    


  75. LEAPMAN MS, Cowan JE, Nguyen HG, Shinohara KK, et al
    Active Surveillance in Younger Men With Prostate Cancer.
    J Clin Oncol. 2017 Mar 27:JCO2016680058. doi: 10.1200/JCO.2016.68.0058.
    PubMed     Text format     Abstract available


  76. CHIN J, Rumble RB, Kollmeier M, Heath E, et al
    Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.
    J Clin Oncol. 2017 Mar 27:JCO2016720466. doi: 10.1200/JCO.2016.72.0466.
    PubMed     Text format     Abstract available


  77. SMITH BYRNE K, Castano JM, Chirlaque MD, Lilja H, et al
    Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC).
    J Clin Oncol. 2017 Mar 6:JCO2016700062. doi: 10.1200/JCO.2016.70.0062.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: